UK’s CMA Doubles Down On Liothyronine Objections

Following Ruling On Unfair Pricing For Phenytoin In March

 
• By David Wallace
Pills_GBP
The CMA insists Advanz charged excessive and unfair UK prices for liothyronine • Source: Shutterstock

More from Regulation

More from Policy & Regulation